Company intelligence / Profile preview

Debiopharm

Lausanne, Vaud, Switzerlanddebiopharm.com ↗

Ownership: Private
Employees: ~400
Development stage: Commercial

Overview

Debiopharm has developed two blockbuster therapies - oxaliplatin for colorectal cancer and triptorelin for prostate cancer and central precocious puberty. They also have a potential third blockbuster drug for Head & Neck Cancer currently in phase III development[3].

Therapeutic areas: Women's HealthOncologyEndocrinologyInfectious Diseases
Modalities: Small moleculesbiologics
Industry: Biotech

Drug pipeline

40 assets

triptorelin

Approved

39 more assets in the full pipeline.

Request access →

Partnerships

Ipsen Pharma (for Decapeptyl/triptorelin)Allergan (former partner for Trelstar)Ubiquigent Limited

Beyond the preview

Go deeper on Debiopharm.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Debiopharm.

Explore the full profile